199 related articles for article (PubMed ID: 7109938)
1. [Hepatic elimination of indocyanine green and antipyrine in patients with chronic liver disease].
Kuntz HD; Meessen D; May B
Med Welt; 1982 Jun; 33(25):909-10. PubMed ID: 7109938
[No Abstract] [Full Text] [Related]
2. Proceedings: The influence of chronic liver disease on the elimination of d-propranolol, anti-pyrine, and indocyanine green.
Branch RA; James JA; Read AE
Gut; 1974 Oct; 15(10):837-8. PubMed ID: 4434964
[No Abstract] [Full Text] [Related]
3. [Different elimination velocity of indocyanine green in liver diseases of various severity].
Brügmann E
Z Gesamte Inn Med; 1973 Sep; 28(17):523-6. PubMed ID: 4767186
[No Abstract] [Full Text] [Related]
4. Disposition of aminopyrine, antipyrine, diazepam, and indocyanine green in patients with liver disease or on anticonvulsant drug therapy: diazepam breath test and correlations in drug elimination.
Hepner GW; Vesell ES; Lipton A; Harvey HA; Wilkinson GR; Schenker S
J Lab Clin Med; 1977 Sep; 90(3):440-56. PubMed ID: 894100
[No Abstract] [Full Text] [Related]
5. The clearance of antipyrine and indocyanine green in normal subjects and in patients with chronic lever disease.
Branch RA; James JA; Read AE
Clin Pharmacol Ther; 1976 Jul; 20(1):81-9. PubMed ID: 1277728
[TBL] [Abstract][Full Text] [Related]
6. Beta-adrenoceptor blocking drugs and cytochrome P-450: the influence of propranolol treatment on caffeine, antipyrine, D-glucaric acid and indocyanine green elimination in patients with hepatic disorders.
Traeger A; Horváth T; Rechenbach C; Jávor T
Int J Clin Pharmacol Res; 1986; 6(3):235-9. PubMed ID: 3744626
[TBL] [Abstract][Full Text] [Related]
7. Hepatic clearances of antipyrine, indocyanine green, and galactose in normal subjects and in patients with chronic liver diseases.
Kawasaki S; Sugiyama Y; Iga T; Hanano M; Beppu T; Sugiura M; Sanjo K; Idezuki Y
Clin Pharmacol Ther; 1988 Aug; 44(2):217-24. PubMed ID: 3396264
[TBL] [Abstract][Full Text] [Related]
8. Half-life time or clearance of indocyanine green in patients with liver disease.
Gilmore IT; Marigold JH; Thompson RP
Hepatogastroenterology; 1982 Apr; 29(2):55-7. PubMed ID: 7084884
[TBL] [Abstract][Full Text] [Related]
9. [Comparative study on the elimination of pindolol (visken) and antipyrin in patients with liver diseases].
Ohnhaus EE; Münch U; Meier J
Schweiz Med Wochenschr; 1976 Dec; 106(49):1748-50. PubMed ID: 1013699
[TBL] [Abstract][Full Text] [Related]
10. Hepatic metabolic function in patients receiving long-term methotrexate therapy: comparison with topically treated psoriatics, patient controls and cirrhotics.
Birnie GG; Fitzsimons CP; Czarnecki D; Cooke A; Scobie G; Brodie MJ
Hepatogastroenterology; 1985 Aug; 32(4):163-7. PubMed ID: 2865199
[TBL] [Abstract][Full Text] [Related]
11. [Determination of indocyanine green clearance by means of dichromatic ear densitometry for evaluation of liver function].
Paumgartner G; Longueville J; Leevy CM
Wien Z Inn Med; 1967; 48(6):227-35. PubMed ID: 5620283
[No Abstract] [Full Text] [Related]
12. The relationship between liver volume, antipyrine clearance and indocyanine green clearance before and after phenobarbitone administration in man.
Roberts CJ; Jackson L; Halliwell M; Branch RA
Br J Clin Pharmacol; 1976 Oct; 3(5):907-13. PubMed ID: 973986
[TBL] [Abstract][Full Text] [Related]
13. Proceedings: The relationships between liver volume and the disposition of antipyrine and indocyanine green before and after phenobarbitone treatment.
Branch RA; Halliwell M; Jackson L; Roberts CJ
Br J Pharmacol; 1975 Oct; 55(2):263P. PubMed ID: 1201403
[No Abstract] [Full Text] [Related]
14. Major determinants of drug disposition in chronic liver disease: a study with indocyanine green and antipyrine [proceedings].
Branch RA; James JA; Read AE
Br J Clin Pharmacol; 1975 Aug; 2(4):370P-371P. PubMed ID: 1234003
[No Abstract] [Full Text] [Related]
15. Investigation of the hepatic excretion mechanism of indocyanine green in patients with liver disease. II. Two-compartment analysis for in vivo kinetics.
Nakagawa S; Araki K; Nagashima H
Kumamoto Med J; 1977 Mar; 30(1):1-8. PubMed ID: 611312
[No Abstract] [Full Text] [Related]
16. Impairment of drug elimination in patients with liver disease.
Narang AP; Datta DV; Mathur VS
Int J Clin Pharmacol Ther Toxicol; 1985 Jan; 23(1):28-32. PubMed ID: 3988389
[TBL] [Abstract][Full Text] [Related]
17. [Correlations of kinetics of antipyrine, indocyanine green and bromosulfophthalein in healthy subjects and in patients with cardiovascular diseases].
Adamska-Dyniewska H; Kowalczyk L
Pol Tyg Lek; 1978 Jul; 33(29):1143-5. PubMed ID: 704415
[No Abstract] [Full Text] [Related]
18. [Excretion rate of indocyanine green in liver diseases of various severity].
Teichmann W; Brügmann E; Schulz H
Orv Hetil; 1973 May; 114(20):1170-1. PubMed ID: 4704298
[No Abstract] [Full Text] [Related]
19. Correlation between biochemical tests, parameters of drug elimination and hepatic enzyme induction in chronic liver diseases.
Horváth T; Pár A; Beró T; Kádas I; Fábián C; Jávor T
Acta Med Hung; 1983; 40(4):203-13. PubMed ID: 6674914
[TBL] [Abstract][Full Text] [Related]
20. [Liver capacity in the biotransformation of drugs in patients with chronic circulatory failure (kinetics of antipyrine and indocyanine green)].
Adamska-Dyniewska H
Pol Arch Med Wewn; 1978 Oct; 60(4):313-8. PubMed ID: 714726
[No Abstract] [Full Text] [Related]
[Next] [New Search]
